Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case study, a 65-year-old male with hepatocellular carcinoma treated with the PD-1 inhibitor Sintilimab developed alopecia universalis alongside significant tumor regression and complete remission, highlighting a rare immune-related adverse event with effective anti-tumor outcomes.

This study reported cases of post-vaccine telogen effluvium and alopecia among five individuals in Ecuador following a mixed COVID-19 vaccination regimen, typically appearing within 3 to 17 days after inoculation.

In this study, researchers found that a PER3 gene SNP may be pathogenic for a new subtype of dyschromatosis universalis hereditaria, especially when combined with a SASH1 mutation.

This review discusses the onset and characteristics of telogen effluvium following SARS-CoV-2 infection, implicating stress, cytokine release, or viral damage, and reports no new clinical results.

In this study, a case of a patient with dermatomyositis and alopecia universalis showed successful treatment with tofacitinib, suggesting potential responsiveness to janus kinase inhibitors.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This study found that pigmented vellus and upright regrowing hairs are the only predictive trichoscopic markers of hair regrowth in patients with alopecia totalis and universalis.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

This case report describes a patient with alopecia universalis who experienced quick hair regrowth after being treated with alitretinoin.

This letter to the editor reports a case of alopecia universalis occurring alongside minimal change nephrotic syndrome, but it presents no new clinical findings.

A gene mutation causes a rare hereditary hair loss, offering potential for new treatments.

This article reviews the need for a reliable and safe method to prevent alopecia areata from progressing to more severe states and reports no new research findings.

This letter discusses alopecia universalis and Kallman’s Syndrome, and offers no new clinical results.

In this case report, a 30-year-old male with alopecia universalis and autoimmune conditions experienced treatment failure with JAK inhibitors, including ritlecitinib, and developed severe musculoskeletal pain, indicating a potential novel adverse effect that warrants further pharmacovigilance.

This case report describes an Ayurvedic treatment approach in a 48-year-old male with Alopecia Universalis, suggesting potential benefit through subjective assessments; however, detailed clinical results are not provided.

This case study reports the first known instance of successful rapid hair regrowth in a psoriasis patient with alopecia universalis after starting deucravacitinib, suggesting potential for TYK2 inhibitors in managing alopecia areata.

This case study describes a rare instance of alopecia universalis in a Japanese patient following an mRNA COVID-19 vaccination.

In this case report, tofacitinib was initiated in a 20-year-old female with alopecia universalis resistant to topical treatments, but resulted in a mild peripheral neuropathy side effect.

In this case report, treatment with corticosteroid and cyclosporine improved hair growth in a 19-year-old male with alopecia universalis over 51 days.

This review discusses recent advancements in treating alopecia areata, highlighting the promise of Janus kinase inhibitors and platelet-rich plasma therapy, but it reports no new clinical findings.

This study presents a case of treatment-resistant alopecia universalis that successfully responded to a combination of tofacitinib and oral minoxidil, highlighting a potential therapeutic approach for challenging cases of alopecia areata.

This correspondence discusses the treatment of alopecia universalis in a 6-year-old girl using simvastatin/ezetimibe, minoxidil, and prednisolone, but it reports no new clinical findings.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

In this study, a 12-year-old intact male wirehaired fox terrier with testicular neoplasia and alopecia universalis was successfully treated for the alopecia using a combination of ciclosporin and ketoconazole, leading to complete hair regrowth.

This case study reports the clinical features of triple H syndrome in a 25-year-old man, including ACTH deficiency, alopecia universalis, and anterograde amnesia, which were improved with hydrocortisone treatment.

A woman's hair grew back while she was taking sulphasalazine for arthritis.

In this study, treatment of alopecia areata, totalis, and universalis with methyl prednisolone and ACTH injections resulted in complete regrowth in 62% of male and 58% of female patients.

This retrospective cohort study found that individuals with alopecia totalis or universalis have a higher prevalence of systemic autoimmune diseases, particularly endocrine diseases and inflammatory bowel disease, compared to those with patchy alopecia areata.